Merck (MRK) Equity Ratio (2009 - 2026)

Merck has disclosed Equity Ratio across 18 years of filings, most recently posting 0.36 for Q1 2026.

• In Q1 2026, Equity Ratio fell 15.2% year-over-year to 0.36; the TTM figure through Mar 2026 stood at 0.36 (down 15.2% YoY), while the FY2025 annual figure was 0.38, down 2.83% from the prior year.
• Equity Ratio eased to 0.36 in Q1 2026, from 0.38 in the prior quarter.
• Over the last five years, Equity Ratio for MRK reached as high as 0.44 in Q1 2023 and fell as low as 0.35 in Q4 2023.
• The 5-year median for Equity Ratio is 0.39 (2024), against an average of 0.39.
• Annual changes were most pronounced in 2022 — Equity Ratio increased 28.99% — and 2023, when it slipped 16.38%.
• A 5-year view of Equity Ratio shows it stood at 0.42 in 2022, then fell by 16.38% to 0.35 in 2023, then gained by 12.24% to 0.4 in 2024, then declined by 2.83% to 0.38 in 2025, then retreated by 7.34% to 0.36 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.36, 0.38, and 0.4 for Q1 2026, Q4 2025, and Q3 2025 respectively.